Genflow Biosciences Share Discussion Threads

[moneymunch] 07/5/2024 07:00

At least we know the Results are in, maybe their website designer/admin has slept in this morning??? Gla ;-)

[molatovkid] 07/5/2024 06:55

Ummmm.....bit annoying. Emailed Investor Relations.

[cyberbub] 07/5/2024 06:37

This is very unimpressive again. What are they playing at, issuing an RNS saying the results are on the website when they're not?

[steg] 07/5/2024 06:27

Don’t think they are on quite yet, think another rns will appear to say trading resumes at some point

[cyberbub] 07/5/2024 06:22

Er is it just me or are the results *not* on the company's website as stated?

[tim000] 07/5/2024 06:14

I assume the Suspension will be lifted immediately.

[moneymunch] 07/5/2024 06:02

7 May 2024

Genflow Biosciences Plc

("Genflow" or "the Company")

FINAL RESULTS

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases, is pleased to announce its final results for the year ended 31 December 2023. The Annual Report is available to view on the Company's website at www.genflowbio.com

The Company will post the Annual Report to shareholders and provide notice for its Annual General Meeting in the coming weeks.

Genflow is a UK-based biotechnology company focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with advanced age. It is the first longevity biotechnology company to list in Europe and seeks to be a reference company in the European longevity sector.

[moneymunch] 03/5/2024 05:47

24/1/24

Longevity biotech collaborates with Revatis and EXO Biologics on new research into sarcopenia and SIRT6 MRNA delivery.

Longevity biotech Genflow Biosciences has teamed up with Revatis and EXO Biologics on two new longevity research programs, fueled by grants from the Government of Wallonia in Belgium. Genflow is developing gene therapies that target the aging process, with a focus on reducing and delaying age-related diseases.

One of the new research programs, conducted in collaboration with cell therapy company Revatis, is focused on addressing the issue of age-related muscle loss. With funding of €1.34 million, the three-year initiative aims to provide insights into the mechanisms of sarcopenia – the muscle deterioration associated with aging.

Simultaneously, Genflow and exosome-focused biotech EXO Biologics are embarking on a three-year scientific program focusing on mRNA delivery. Supported by a grant of €1.55 million, the initiative will explore an approach using exosomes to encapsulate and transport Genflow’s SIRT6 gene therapy. The ultimate goal is to enable the development of therapeutic interventions for Werner Syndrome, an accelerated aging condition, and other age-related conditions.

Dr Eric Leire, CEO of Genflow said that the new research programs will allow the company to make “meaningful advancements” in the field of longevity.

“Launching both of these programs represents a strategic move to enhance our research capabilities, while contributing to the understanding of age-related conditions,” he said.

Genflow is currently developing a pipeline of SIRT6 gene therapies, with three programs targeting Werner Syndrome, an aggressive form of non-alcoholic fatty liver disease (NASH), and pet longevity. The company’s lead compound is a suspension of an adeno-associated viral vector-based gene therapy based on a variant of the human SIRT6 gene, which is associated with longevity in centenarians.

Disclosure: First Longevity Ltd which operates this website (Longevity.Technology) has a commercial interest in Genflow Biosciences Ltd.

[moneymunch] 02/5/2024 05:40

Revatis

772 followers
1w

Exciting News! Collaboration Alert at Revatis!🔬

We are delighted to announce the expansion of the collaboration between #Trince and #Revatis, marking a significant milestone in our journey. Together, we are proud to introduce the first photoporation platform in Wallonia, developed as part of the Mitosir project under the "BioWin-ATMP collaborative project."

The Mitosir project is dedicated to tackling muscular mitochondrial dysfunction seen in sarcopenia, a significant health issue. For this purpose, we have joined forces with #Genflow, a distinguished industrial partner known for their expertise and intellectual property in Sirtuin peptides, which are essential for mitochondrial function and anti-aging.

We're confident this collaboration will propel research in the realm of muscle health, and we're proud to work in tandem with ULB and the Uliege to explore the fundamental aspects of this critical topic.

Keep an eye out for more thrilling updates on this project! 💪💡

#stemcells #cellgenetherapy #MuscleHealth #Research #Innovation #Revatis #Trince #Genflow #ULB #Uliege #Rise #Photoporation #MitochondrialDysfunction #Sarcopenia #Biowin #wallonierelance

...............



Revatis

772 followers
1d

A nice paper authored by Julien Duysens, our PhD student within the company, made possible through a grant from Wallonia.

Didier Serteyn

Professor Liege University
1d

Latest Development: In our pursuit of advancing tissue engineering and extra cellular Vesicles (exosomes) production, we're working towards a significant milestone. While our goal of harvesting 1 billion muscle derived MSCs (#revatis) from a single muscle microbiopsy (10 mg) at P3 is ambitious, we're making progress step by step.

Stay tuned for updates on our journey! #stemcells #tissueengineering #regenerativemedicine #cellandgenetherapy #equinehealth #exosomes #extracellularvesicles

[northeast14] 01/5/2024 19:16

Lots happening this is our year!

[moneymunch] 01/5/2024 18:27

"be the first to know about our groundbreaking advancements"......sounds encouraging!!! Gla ;-)

[moneymunch] 01/5/2024 18:19

Interesting for Genflow to post the following on Linkedin a couple of hours after suspension. Gla -)

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)



1,594 followers
6h

Stay up-to-date with Genflow Biosciences (LON:GENF) (OTCQB:GENFF)!

Sign up for our latest updates and be the first to know about our groundbreaking advancements. Don't miss important news & exclusive insights - subscribe now:

#GENF #GENFF #biotech #genetherapy #aging

[tim000] 01/5/2024 18:08

Another company I know was unable to publish its results yesterday due to a very last minute delay caused by the auditors requiring third-party information - that too could be described as circumstances beyond its control. Again, it was entirely an auditing matter nothing to do with the company’s business. I imagine this is similar.

[marmiesz] 01/5/2024 18:02

It's the phrase, "and other circumstances beyond its control" that is intriguing. Would seem to indicate there is a third party involved in some way. Marmie

[moneymunch] 01/5/2024 17:04

Yep, probably nothing, but Genflow did ask for the suspension, and so perhaps something??? Gl :-)

NOTICE OF TEMPORARY SUSPENSION OF LISTING FROM THE OFFICIAL LIST

01/05/2024 07:30

TEMPORARY SUSPENSION

GENFLOW BIOSCIENCES PLC

The Financial Conduct Authority ("the FCA") temporarily suspends the securities set out below from the Official List effective from 01/05/2024 07:30 at the request of the company:

[tim000] 01/5/2024 16:56

I haven’t checked on this particular case but usually Suspension occurs automatically because the company has failed to meet a legal deadline.

[tim000] 01/5/2024 16:54

I’m a recent shareholder. Delayed publication of Results is common for smaller companies. The delays are nearly always due to minor accounting queries raised by the auditors which small companies are less able to process quickly. The audit process doesn’t involve auditors knowing price sensitive information unconnected with their auditing role. No doubt the company has great newsflow, but it’s unlikely to be connected with this.

[moneymunch] 01/5/2024 16:40

Hopefully so Northeast, but could be something and nothing, although not sure how many other listed companies would ask for a suspension because the Audit process was taking longer than plannned, and so very intriguing Genflow confirmed "the delay is not related to the Company's cash flow or other underlying economic position". Very interesting and somewhat exciting as we await their next update....it would be amazing if some other party have their financial accounts under due diligence, hence the delay...just a thought. Gl :-)

What Is Due Diligence?

Due diligence is an investigation, audit, or review performed to confirm facts or details of a matter under consideration.

In the financial world, due diligence requires an examination of financial records before entering into a proposed transaction with another party.

[northeast14] 01/5/2024 13:24

I was assume something is happening

[moneymunch] 01/5/2024 07:00

Take over looming????? Gla -)

" due to the audit process taking longer than planned, and other unforeseen circumstances beyond its control"

[moneymunch] 01/5/2024 06:51

Excitement building, just gone UP a notch or two!!! Gla ;-)

[moneymunch] 01/5/2024 06:47

Genflow Biosciences Plc



Temporary Suspension of Listing pending publication of Annual Financial Report



Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases, provides the following update in relation to the publication of its Annual Financial Report ("Annual Report").



The Company was required to publish its Annual Report for the financial year ending 31 December 2023 by 30 April 2024. However, due to the audit process taking longer than planned, and other unforeseen circumstances beyond its control, the Company requires a short amount of additional time. The delay is not related to the Company's cash flow or other underlying economic position.



As a result, at the Company's request, the listing of the Company's ordinary shares on the Main Market of the London Stock Exchange will be temporarily suspended with effect from 7.30 a.m. on 1 May 2024 pending publication of the Annual Report.

[northeast14] 01/5/2024 06:42

That’s a positive suspension, nothing to do with cash flow as stated in follow up RNS. Can only be a good reason for this! Game on!

[molatovkid] 01/5/2024 06:35

RNS out! Suspended !